(AOF) – DMS announces the finalization of the acquisition of Solutions For Tomorrow, a specialist in mobile radiological equipment. The company which develops high-performance medical imaging systems for digital radiology specifies that its acquisition will be carried out entirely by exchange of shares. Solutions For Tomorrow is a Swedish company based in Väckelsång and operating in 35 countries. It was founded in 2011 by three radiology experts, Mattias Guldstrand, Martin Yngvesson and Jan Bååt.
Solutions For Tomorrow’s products are “unmatched in terms of compactness, ergonomics and power” and are protected by 15 patents. They rely on innovative proprietary battery technology called X-tech cell.
DMS highlights that ultramobile products are at the forefront of new trends in the medical imaging market, which is moving towards a more decentralized care model driven by the aging population and the development of chronic diseases such as cancer and heart diseases, making mobile radiology an important factor in maintaining sustainable healthcare systems.
AOF – LEARN MORE
Learn more about the specialty distribution industry
Concerns remain
According to the Federation of Specialized Trade, Procos, in October 2022, activity fell by 1.5% year-on-year. However, the activity of beauty and health (+ 5.2%) and specialized food (+ 3.5%) are dynamic compared to October 2021. Attendance at points of sale was very impacted by the problems fuel and unfavorable weather. Compared to October 2019, a pre-covid year, the drop in attendance is very sharp (-20.9% in October). Shopping centers and the outskirts are more impacted than city centers with a gap of four to five points.
There are several reasons for concern for the future. The players are experiencing a very significant jaws effect given the increase in their operating costs while the evolution of demand is very uncertain. Very few brands can pass on the increase in their costs in sales prices. The federation therefore asks, among other things, to limit the indexation of the Commercial Rent Index to + 3.5% for the rents of all companies in 2023. It also invokes an absolute emergency: cap the price of energy for 2023 and retroact on contracts already signed to prevent the rate of failures from accelerating.
Learn more about the Pharmacy sector
Biotechs put to the test
These companies are suffering from a much less favorable economic cycle, which is reflected in particular by a drop in venture capital financing of start-ups. These companies are therefore obliged to carry out layoff plans. Added to this is a much more restrictive regulatory framework. First, in the United States, measures linked to the Inflation Reduction Act (IRA) could have a strong impact on the margins of stakeholders. Indeed, from 2026, the federal Medicare program will be able to renegotiate the price of drugs marketed for nine years (chemical) or 13 years (biological), with discounts that could range from 35 to 60% for biotechs. Likewise, in Europe, with the new drug regulations presented in Brussels in April, the duration of patent protection will be reduced if the innovative treatment is not marketed in all member countries within two years.